Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2009

View Archived Issues

Partial responses to interleukin-21 seen in ongoing phase II metastatic melanoma study

Bevacizumab safe in first 300 patients enrolled in phase III melanoma trial

Bazedoxifene coupled with conjugated estrogens improves menopausal symptoms in 3 phase III trials

2009 an important year for Protalix Biotherapeutics' pGlcCerase

Novel VEGFR-2 inhibitors identified by Santen for the treatment of cancer

Rituximab safe and effective as rescue therapy in idiopathic systemic vasculitis patients

Japan Tobacco presents free fatty acid receptor 1 agonists as antidiabetics

Novel antibacterial agents described by Prolysis

Merck & Co. claims T-type calcium channel blockers as antiepileptic drugs

Germany to fund clinical research in colorectal cancer using Epigenomics' mSEPT9

KB-R7943 provides neuroprotection in model of ischemic injury of CNS white matter

Hematide increases hemoglobin response in chronic kidney disease patients; phase II trial suggests

Nanowired-based delivery of H-290/51 confers neuroprotection in rat model of heat stroke

Sciele Pharma acquires global rights for PSD-502 from Plethora Solutions

CureVac commences mRNA vaccine clinical study in non-small cell lung cancer

Medinox reports clinical results for naproxen prodrug, LT-NS001

Emisphere reports data from oral GLP-1 and PYY3-36 with Eligen technology

Senesco's Factor 5A1 siRNA improves survival in H1N1-infected mice

FDA extends review timeline for Centocor's BLA for Stelara for plaque psoriasis

AEG-35156 displays evidence of clinical activity in first-in-man phase I trial in cancer patients

THRX-200495 confers in vivo bronchoprotection via both muscarinic and beta2-adrenergic receptors

Neutrophil elastase inhibitor POL-6014 shows preclinical potential for the treatment of lung disease

FDA files for standard review Warner Chilcott's NDA for oral contraceptive WC-3016

Neoprobe commences second phase III Lymphoseek trial

Companies commence Nexavar/Tarceva combination trial in liver cancer

ImmuneRegen submits IND to FDA to initiate human clinical testing of Homspera

EMEA validates Gilead's MAA for regadenoson for radionuclide MPI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...